PortfoliosLab logo

Bone Biologics Corporation (BBLG)

Equity · Currency in USD · Last updated Mar 28, 2023

Share Price Chart


Loading data...

Performance

The chart shows the growth of $10,000 invested in Bone Biologics Corporation in Oct 2022 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $22 for a total return of roughly -99.78%. All prices are adjusted for splits and dividends.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2023FebruaryMarch
-99.78%
-4.96%
BBLG (Bone Biologics Corporation)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with BBLG

Bone Biologics Corporation

Return

Bone Biologics Corporation had a return of 8.57% year-to-date (YTD) and -91.94% in the last 12 months. Over the past 10 years, Bone Biologics Corporation had an annualized return of -95.68%, outperforming the S&P 500 benchmark which had an annualized return of -2.58%.


PeriodReturnBenchmark
1 month-24.50%0.19%
Year-To-Date8.57%3.59%
6 months-80.17%7.70%
1 year-91.94%-12.45%
5 years (annualized)-97.54%-2.83%
10 years (annualized)-95.68%-2.58%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202334.76%4.24%
2022-21.64%-57.14%-33.33%-30.00%

Sharpe Ratio Chart

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Bone Biologics Corporation Sharpe ratio is -0.90. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.

The chart below displays rolling 12-month Sharpe Ratio.


-0.90-0.80-0.70-0.60-0.50-0.40-0.30-0.20NovemberDecember2023FebruaryMarch
-0.90
-0.52
BBLG (Bone Biologics Corporation)
Benchmark (^GSPC)

Dividend History


Bone Biologics Corporation doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%NovemberDecember2023FebruaryMarch
-99.85%
-17.08%
BBLG (Bone Biologics Corporation)
Benchmark (^GSPC)

Worst Drawdowns

The table below shows the maximum drawdowns of the Bone Biologics Corporation. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Bone Biologics Corporation is 99.87%, recorded on Dec 28, 2022. The portfolio has not recovered from it yet.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.87%Aug 17, 2017380Dec 28, 2022
-78.45%Aug 18, 201618Jan 3, 201717Jul 18, 201735
-2%Jul 22, 20161Jul 22, 20161Aug 8, 20162

Volatility Chart

Current Bone Biologics Corporation volatility is 59.85%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.


0.00%50.00%100.00%150.00%200.00%250.00%NovemberDecember2023FebruaryMarch
59.85%
17.88%
BBLG (Bone Biologics Corporation)
Benchmark (^GSPC)